openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI)

11-12-2019 09:59 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares.

An investigation on behalf of current long term investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Karyopharm Therapeutics Inc..

Investors who are current long term investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: KPTI stocks follows a lawsuit filed against Karyopharm Therapeutics Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: KPTI stocks, concerns whether certain Karyopharm Therapeutics Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges that the defendants violated Federal Securities Laws. The plaintiff claims violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) common stock during the time period of March 2, 2017 and February 22, 2019, and violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 on behalf of all persons who purchased or otherwise acquired Karyopharm Therapeutics Inc. (NASDAQ: KPTI common stock in or traceable to the Company's public offerings of common stock conducted on or around April 28, 2017 and May 7, 2018.
More specifically, the plaintiff alleges that the Defendants' material misrepresentations and omissions center on Defendants' claims regarding results from clinical trials for selinexor's treatment of patients with certain types of blood cancer, that the, Defendants claimed that selinexor studies showed that selinexor was "well-tolerated" by patients and explained that there were "no new clinically significant adverse events in the patients receiving selinexor", and that the Company repeatedly touted the commercial prospects for selinexor and consistently described selinexor as having a "predictable and manageable tolerability profile" and a "very nice safety profile”, while in reality, selinexor was unsafe with limited efficacy.

Those who purchased shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) here

News-ID: 1865920 • Views: 452

More Releases from Shareholders Foundation

Lawsuit filed for Investors in Energy Transfer LP (NYSE: ET) over alleged Mislea …
An investor in Energy Transfer LP (NYSE: ET) filed a lawsuit over alleged violations of Federal Securities Laws by Energy Transfer LP in connection with certain allegedly false and misleading statements. Investors who purchased units of Energy Transfer LP (NYSE: ET) have certain options and for certain investors are short and strict deadlines running. Deadline: January 20, 2020. NYSE: ET investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Investigation announced for Investors in shares of CBL & Associates Properties, …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at CBL & Associates Properties, Inc. Investors who purchased shares of CBL & Associates Properties, Inc (NYSE: CBL) and currently hold any of those NYSE: CBL shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain CBL & Associates Properties
Lawsuit filed for Investors in shares of Aurora Cannabis Inc. (NYSE: ACB)
The Shareholders Foundation announced that an investor, who purchased shares of Aurora Cannabis Inc. (NYSE: ACB), filed a lawsuit over alleged violations of Federal Securities Laws by Aurora Cannabis Inc. Investors who purchased shares of Aurora Cannabis Inc. (NYSE: ACB), have certain options and for certain investors are short and strict deadlines running. Deadline: January 21, 2020. NYSE: ACB investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Verb Technology Com …
An investigation on behalf of current long-term investors in shares of Verb Technology Company, Inc. (NASDAQ: VERB) concerning potential breaches of fiduciary duties by certain directors and officers of Verb Technology Company, Inc. was announced. Investors who are current long term investors in Verb Technology Company, Inc. (NASDAQ: VERB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a

All 5 Releases


More Releases for Karyopharm

Hematological Cancers Therapeutics Market To Reach $66.34 Billion By 2026 | Top …
According to the current analysis of Reports and Data, the global hematological cancers therapeutics market accounted for USD 31.32 Billion in 2018 and is expected to reach USD 66.34 billion by 2026 , at a CAGR of 9.8 percent. Hematology Cancer Therapeutics market is majorly driven by a high incidence of blood cancer across the globe and favorable funding scenario for the research and development of therapeutics for blood cancer.
Pet Cancer Therapeutics Market Size 2019 by Top Key Players: Aratana Therapeutic …
Market Study Report, LLC, has compiled a detailed study on the Pet Cancer Therapeutics market which provides a brief summary of the growth trends influencing the market. The report also includes significant insights pertaining to the profitability graph, market share, regional proliferation and SWOT analysis of this business vertical. The report further illustrates the status of key players in the competitive setting of the Pet Cancer Therapeutics market, while expanding
New Report Focusing on Pet Cancer Therapeutics Market Growth Study in Detail alo …
Pet cancer therapeutics refers to various therapeutic agents used to treat cancer in pet animals. The success rate of various treatments, preventing and curing neoplasia and cancer in the pet population, has observed a significant rise over the past few years, as a result of the recent advancements in early recognition, diagnosis, and treatment. The growing prevalence of several types of cancers in cats and dogs, as well as increase
Pet Cancer Therapeutics Market Explore Future Growth 2018-2026 by Global Top Pla …
Coherent Market Insights has announced the addition of the “Pet Cancer Therapeutics Market Size Status and Forecast 2026”, The report classifies the global Pet Cancer Therapeutics Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. This report studies the global Pet Cancer Therapeutics Speaker market, analyzes and researches the Pet Cancer Therapeutics Speaker development status and forecast in
Pet Cancer Therapeutics Market 2018 Global Research and Top Manufacturers: Boehr …
Pet Cancer Therapeutics Market report offers the up-to-date industry information and enterprise future developments, allowing you to recognize the goods and end customers driving sales increase and profitability. This pet cancer therapeutics report consists of the forecasts up to 2023, analysis and dialogue of important enterprise developments, market length, market share estimates and profiles of the leading industry players. The worldwide market for Pet Cancer Therapeutics is expected to grow at
Pet Cancer Therapeutics Market Explore Future Growth 2017-2025 by Global Top Pla …
Coherent Market Insights has announced the addition of the “Pet Cancer Therapeutics Market Size Status and Forecast 2026”, The report classifies the global Pet Cancer Therapeutics Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. This report studies the global Pet Cancer Therapeutics Speaker market, analyzes and researches the Pet Cancer Therapeutics Speaker development status and forecast in